169 related articles for article (PubMed ID: 28661064)
1. Multifunctional Polymeric Micelles for Combining Chelation and Detection of Iron in Living Cells.
Liu Z; Purro M; Qiao J; Xiong MP
Adv Healthc Mater; 2017 Sep; 6(17):. PubMed ID: 28661064
[TBL] [Abstract][Full Text] [Related]
2. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
Liu Z; Lin TM; Purro M; Xiong MP
ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
4. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
5. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
Liu Z; Qiao J; Nagy T; Xiong MP
J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
[TBL] [Abstract][Full Text] [Related]
6. Oxidation-Induced Degradable Nanogels for Iron Chelation.
Liu Z; Wang Y; Purro M; Xiong MP
Sci Rep; 2016 Feb; 6():20923. PubMed ID: 26868174
[TBL] [Abstract][Full Text] [Related]
7. Novel DFO-functionalized mesoporous silica for iron sensing. Part 2. Experimental detection of free iron concentration (pFe) in urine samples.
Alberti G; Emma G; Colleoni R; Pesavento M; Nurchi VM; Biesuz R
Analyst; 2014 Aug; 139(16):3940-8. PubMed ID: 24883429
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Wu D; Wen X; Liu W; Hu H; Ye B; Zhou Y
Drug Des Devel Ther; 2018; 12():1081-1091. PubMed ID: 29760547
[TBL] [Abstract][Full Text] [Related]
9. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
11. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
13. From small deferiprone to macromolecular micelles: Self-assembly enhances iron chelation.
Huang X; Lu D; Ma Y; Zhang L; Wang L; Deng J; Wang Z; Zhao Y
J Colloid Interface Sci; 2019 Jan; 533():375-384. PubMed ID: 30172148
[TBL] [Abstract][Full Text] [Related]
14. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
[TBL] [Abstract][Full Text] [Related]
15. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
16. Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.
Bibi H; Vinokur V; Waisman D; Elenberg Y; Landesberg A; Faingersh A; Yadid M; Brod V; Pesin J; Berenshtein E; Eliashar R; Chevion M
Redox Biol; 2014; 2():814-9. PubMed ID: 25009783
[TBL] [Abstract][Full Text] [Related]
17. A Water-Soluble Chitosan Derivative for the Release of Bioactive Deferoxamine.
Michailidou G; Li Y; Zamboulis A; Karlioti G; Meimaroglou D; Pantopoulos K; Bikiaris DN
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255991
[TBL] [Abstract][Full Text] [Related]
18. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy.
Xu L; Guan R; Yu B; Li Y; Liu H; Jiang Y
Int J Pharm; 2022 Sep; 625():122136. PubMed ID: 36029994
[TBL] [Abstract][Full Text] [Related]
19. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
20. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]